glp-1 antagonist natural receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-1 Supplement for Weight Management

Patients who underwent small and large bowel resection were randomly assigned to receive daily infusions of 0.03 mg/kg of ipamorelin or a placebo from day 1 to 7 following surgery

For most people, the result is some temporary nausea, a bit of bloating, or a few days of looser stools

doi.org/10.1016/j.molmed.2005.07.004 Crockford, D., et al

In fact, demand for GLP-1 therapies has grown so rapidly that the World Health Organization (WHO) issued an advisory to its members last December, warning of the spread of falsified and substandard products that threaten patient safety and public trust

Made in the UK

Physiology-Endocrinology Metabolism 303 (1), E122E131